Skip to main content

Table 2 Patient characteristics

From: Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis

  With fixed-dose combination drugs (cases) Without fixed-dose combination drugs (controls) p (χ2 tests)
Number of patients 542   9664   
Gender      0.1735
   Male 198 36.5% 3814 39.5%  
Age category      0.2087
  ≤64 years 212 39.1% 3729 38.6%  
  65–74 years 153 28.2% 3047 31.5%  
  ≥75 177 32.7% 2888 29.9%  
Drug use before index      <.0001
  ARB and CCB combination 405 74.7% 5269 54.5%  
  ARB alone 104 19.2% 3938 40.7%  
Number of concomitant drugs      0.4567
  7 or more 74 13.7% 1214 12.6%  
Diabetes drugs      0.0582
  Users 153 28.2% 2379 24.6%  
Hyperlipidemia drugs      0.8094
  Users 236 43.5% 4157 43.0%  
Prescribers’ characteristics      
  Doctors at clinics (no bed) 111 20.5% 993 10.3% <.0001
  Cardiovascular specialists 172 31.7% 2457 25.4% 0.0011
  1. ARB: angiotensin-receptor blocker, CCB: calcium-channel blocker.